Trials / Completed
CompletedNCT03951103
rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
A Chart Review Study of Patients With Haemophilia A With Inhibitors Treated With rFVIIIFc (Elocta®) for Immune Tolerance Induction
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Swedish Orphan Biovitrum · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A chart review study of patients with haemophilia A with inhibitors treated with rFVIIIFc (Elocta®) for immune tolerance induction.
Detailed description
A multicenter, international, non- interventional, retrospective and prospective medical chart review study. Data will be collected from medical records for patients diagnosed with haemophilia A who have been, or who are currently, treated with rFVIIIFc for ITI . The study will be descriptive in nature and report on baseline characteristics, treatment and outcomes for patients who have been, or who are currently, treated with rFVIIIFc for ITI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | rFVIIIFc | Drug according to prescription |
Timeline
- Start date
- 2018-11-07
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2019-05-15
- Last updated
- 2024-09-19
Locations
18 sites across 8 countries: France, Germany, Ireland, Italy, Kuwait, Norway, Saudi Arabia, Switzerland
Source: ClinicalTrials.gov record NCT03951103. Inclusion in this directory is not an endorsement.